Departments of Radiation Oncology, Surgical Oncology and Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Department of Radiation Oncology, British Columbia Cancer Agency-Vancouver Island Centre, University of British Columbia, Victoria, BC, Canada.
Breast Cancer Res Treat. 2010 Sep;123(2):597-605. doi: 10.1007/s10549-010-0829-8. Epub 2010 Mar 20.
Recent pre-clinical models suggest that radiation can promote tumor aggressiveness. We hypothesized that if this were occurring clinically, locoregional recurrences (LRRs) after postmastectomy radiation therapy (PMRT) would lead to lower survival than LRR after mastectomy alone. This study used two independent datasets to compare survival after LRR in women treated with versus without PMRT. Data from 229 LRR cases among 1,500 patients enrolled on prospective trials at the MD Anderson Cancer Center (MDA), and 66 LRR cases among 318 patients enrolled in the British Columbia Cancer Agency (BCCA) PMRT randomized trial were analyzed. In the MDA non-randomized dataset, 189/1031 had LRR after mastectomy alone and 40/469 had LRR after PMRT. In the randomized BC trial dataset, 52/158 had LRR after mastectomy alone and 14/160 had LRR after PMRT. In both datasets, survival was calculated from the time of LRR to death. Analysis of MDA data shows that in all LRR cases regardless of distant metastasis (DM), 5/10-year OS were 50/34% without PMRT and 27/19% after PMRT (P = 0.006). However, PMRT-treated patients had increased risk factors for DM (advanced T and N stages) and more PMRT-treated patients developed DM prior to LRR (63 vs. 34%, P = 0.005). Analyzing only patients will an isolated LRR (without previous or simultaneous, DMV), there was no OS difference between groups (P = 0.33). Analysis of BCCA data shows that distributions of T and N stages were similar in patients with LRR after mastectomy alone versus after PMRT. DM free survival after any LRR and after isolated LRR were similar in mastectomy alone versus PMRT-treated patients (P = 0.75, P = 0.26, respectively). Overall survival after any LRR and after isolated LRR were also similar in the two groups (P = 0.93, P = 0.28, respectively). Patients who develop LRR after mastectomy alone have high rates of DM and poor OS but these rates are not affected by the use of PMRT at the time of primary treatment. These data do not support the hypothesis that irradiation promotes biologically aggressive local recurrences.
最近的临床前模型表明,辐射会促进肿瘤的侵袭性。我们假设,如果这种情况在临床上发生,那么乳房切除术后放疗 (PMRT) 后的局部区域复发 (LRR) 会导致生存率低于单纯乳房切除术的 LRR。本研究使用两个独立的数据集来比较接受 PMRT 与未接受 PMRT 的女性 LRR 后的生存情况。该研究分析了 MD 安德森癌症中心 (MDA) 前瞻性试验中 1500 名患者中的 229 例 LRR 病例和不列颠哥伦比亚癌症署 (BCCA) PMRT 随机试验中 318 名患者中的 66 例 LRR 病例的数据。在 MDA 非随机数据集,1031 例中 189 例单纯乳房切除术 LRR,469 例中 40 例 PMRT 后 LRR。在随机 BC 试验数据集中,158 例单纯乳房切除术 LRR 中有 52 例,160 例 PMRT 后 LRR 中有 14 例。在这两个数据集,生存时间均从 LRR 时间计算至死亡时间。MDA 数据的分析显示,无论远处转移 (DM) 如何,在所有 LRR 病例中,未接受 PMRT 的 5/10 年 OS 为 50/34%,接受 PMRT 后的 OS 为 27/19%(P = 0.006)。然而,PMRT 治疗的患者具有 DM(晚期 T 和 N 期)的更多危险因素,并且更多的 PMRT 治疗的患者在发生 LRR 之前发生 DM(63% vs. 34%,P = 0.005)。仅分析孤立性 LRR(无先前或同时性 DMV)的患者,两组之间无生存差异(P = 0.33)。对 BCCA 数据的分析显示,在单独接受乳房切除术或 PMRT 治疗的 LRR 患者中,T 和 N 期的分布相似。任何 LRR 和孤立性 LRR 后的 DM 无复发生存在单独接受乳房切除术或 PMRT 治疗的患者中相似(P = 0.75,P = 0.26)。两组之间任何 LRR 和孤立性 LRR 后的总生存也相似(P = 0.93,P = 0.28)。单独接受乳房切除术的患者发生 LRR 后具有高 DM 发生率和不良 OS,但这些发生率不受初始治疗时使用 PMRT 的影响。这些数据不支持照射促进具有生物侵袭性的局部复发的假设。